US public health officials have been ordered to immediately suspend all collaboration with the World Health Organization (WHO ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Acarizax (12 ...

The presentation of Japanese drugmaker Takeda’s latest financial results were presented Thursday, though they took a back ...

In a long-term succession plan, the board of directors at Japan’s largest drugmaker Takeda has made the decision unanimously ...

Swiss pharma giant Roche today released full-year 2024 financials, showing that group sales grew 7% at constant exchange ...

Evaxion Biotech has priced a public offering, seeking to raise $10.8 million before expenses, with closing anticipated tomorrow.

The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...

The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio. The expansion is fueled by increased ...

US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...

Cullinan Therapeutics and its partner Taiho Pharmaceutical have reported a win for zipalertinib, with the primary endpoint of a Phase IIb trial being met. The data, which include a positive safety ...

Danish CNS specialist Lundbeck announced positive results from the 12-month open-label extension of the Phase Ib/IIa PACIFIC trial, evaluating bexicaserin in participants aged 12-65 with developmental ...

French pharma major Sanofi (Euronext: SAN) has met analyst estimates for its fourth-quarter 2024 profit and confirmed plans for a 5 billion euro ($5.5 billion) share buyback program in 2025. The ...